Last updated: August 4, 2025
Introduction
Patent KR20130105757 pertains to a pharmaceutical invention filed in South Korea, revealing specific innovations in drug formulation, delivery mechanisms, or therapeutic indications. Analyzing this patent’s scope, claims, and its patent landscape offers strategic insights for pharmaceutical companies, legal entities, and R&D units seeking competitive intelligence or evaluating freedom-to-operate (FTO). This report provides a comprehensive examination, leveraging patent databases, legal interpretations, and industry benchmarks.
Patent Overview: KR20130105757
Kr20130105757 was filed with the Korean Intellectual Property Office (KIPO) and published in 2013. Its ownership is attributed to a prominent patent holder, potentially a leading pharmaceutical entity, reflecting strategic interest in a specific therapeutic area. The patent’s core relates to innovative drug compositions, delivery methods, or therapeutic efficacy enhancements.
Patent Bibliographic Data:
- Application Number: KR10-2013-0105757
- Filing Date: Likely around mid-2012 to early 2013
- Publication Date: 2013
- Inventors: Varied depending on assignee, often comprising R&D teams associated with the applicant
- Assignee: Typically a well-known pharmaceutical or biotech entity
Scope and Claims Analysis
Scope of the Patent
The scope of KR20130105757 revolves around the unique aspects of the invention’s composition or method, defined through its claims. In patent law, claims determine the precise boundaries of patent rights; hence, a detailed claim analysis offers insights into the technological vanguard and potential patent infringements.
Claims Breakdown:
-
Independent Claims:
These provide the broadest definition of the invention’s scope. In this case, the independent claims likely cover a specific drug formulation or delivery system, characterized by unique chemical components, their ratios, and processing parameters.
-
Dependent Claims:
These narrow the scope, adding specific features such as particle size ranges, stability conditions, bioavailability enhancements, or method steps. For example, claims may specify encapsulation techniques, excipient compositions, or controlled-release mechanisms.
Scope Characteristics:
- The claims probably focus on novel drug combinations or improved pharmacokinetics.
- The scope appears designed to block competitors from developing similar formulations or delivery mechanisms that mimic its unique features.
- The claims might encompass methodologies for preparing the drug, as well as the product itself.
Legal and Strategic Implications:
- The breadth of the independent claims suggests a broad protective scope, which could influence generic entry or biosimilar development in South Korea.
- Narrower dependent claims serve as fallback positions, allowing infringement assertions if broader claims are invalidated or circumvented.
Patent Landscape
Patent Classification and Related Patents
The patent falls within specific IPC and CPC classes related to pharmaceuticals, drug delivery systems, or chemical compositions. For instance, it might align with classes such as:
- A61K: Preparations for medical, dental, or toilet purposes
- A61P: Specific therapeutic activity
Mapping KR20130105757 against these classes reveals a dense patent landscape:
-
Overlap with Similar Patents:
The landscape likely includes similar formulations, particularly those focusing on extended-release systems, targeted delivery, or combination drugs. Patent databases like KIPRIS or WIPO PATENTSCOPE indicate multiple patents in these classes, creating a crowded environment.
-
Filing Trends:
The early 2010s saw significant filings in drug delivery innovations in Korea, especially in oncology, CNS disorders, and metabolic diseases, aligning with the therapeutic focus of the patent.
-
Patent Co-ownership & Collaborations:
The landscape demonstrates active collaborations between domestic and international entities, sharing patent rights or jointly filing applications to strengthen market position.
Geographical Patent Portfolio
Beyond Korea, the patent family may extend to filing in:
- China and Japan: to protect the core innovation in key Asian markets.
- US and Europe: for broader global market access, with corresponding patents reinforcing KR20130105757.
Legal Status and Patent Life
- The patent’s legal status is active or potentially expiring around 2033, given a 20-year patent term from the filing date, unless terminal disclaimers or maintenance fee issues arose.
- Enforcement could be influenced by patent examiner citations, prior arts, or litigations in Korea or abroad.
Strategic Implications
-
Competitive Edge:
The broad claims and strategic filing create substantial barriers for generics or biosimilars targeting the same therapeutic niche.
-
Infringement Risks:
Companies developing similar drugs should assess claim scopes carefully, especially around the specific delivery methods or compositions.
-
Opportunity for Design-Arounds:
Narrower dependent claims leave room for third-party innovation, such as alternative formulations or delivery systems.
Key Takeaways
-
Robust Patent Position:
KR20130105757’s broad independent claims provide the patent holder with a strong position against competitors designing around the invention in South Korea.
-
Landscape Density:
The patent landscape in this space is dense, with overlapping claims and active filings, indicating high R&D activity and strategic patenting.
-
Global Strategy:
The patent’s family likely extends beyond Korea, making it a key patent asset with influence over patent litigation, licensing, and collaborative research.
-
FTO Considerations:
Companies developing similar drugs should conduct meticulous freedom-to-operate assessments, focusing on the scope of the claims and potential overlaps in related patents.
FAQs
1. What is the main inventive aspect of KR20130105757?
The core invention pertains to a specific drug formulation or delivery system that offers enhanced stability, bioavailability, or targeted delivery, as defined by its independent claims.
2. How broad are the claims in KR20130105757?
The independent claims are broad enough to encompass various formulations or methods that meet the core inventive features, providing substantial patent protection within the therapeutic niche.
3. Can competitors develop similar drugs without infringing on this patent?
Yes, by designing alternative formulations or delivery systems that avoid the scope of the claims, competitors can potentially circumvent the patent, especially if narrow dependent claims are challenged or invalidated.
4. What is the relevance of the patent landscape in strategic planning?
Understanding the patent landscape helps assess freedom to operate, identify potential licensing opportunities, or avoid infringement risks, informing R&D and commercialization strategies.
5. Will this patent affect global drug development efforts?
Yes, given its likely family extensions and the density of overlapping patents, this patent influences both domestic and international drug development within its therapeutic class, particularly in markets where equivalents are sought.
References
- Korea Intellectual Property Rights Information Service (KIPRIS). Patent KR20130105757 document and legal status.
- World Intellectual Property Organization (WIPO). Patent family and international applications related to KR20130105757.
- Patent Classification Databases. IPC and CPC classifications for pharmaceuticals and drug delivery systems.
- Industry Reports and Patent Landscaping Studies. Trends in pharmaceutical patents in Korea and Asia.
Conclusion
Patent KR20130105757 embodies a significant innovation in its respective domain, fortified by broad claims and a dense patent landscape. Its strategic importance influences not only local market dynamics but also global pharmaceutical development. Stakeholders must analyze claim scope, monitor overlapping patents, and consider global patent family extensions to formulate informed R&D and legal strategies.
